Blood:纤维蛋白原在组织损伤和炎症中的多重作用

2018-12-08 MedSci MedSci原创

止血和纤溶系统的经典作用是维持血管的完整性。任一系统异常都可能导致出血或血栓形成伴血管闭塞的主要病理终点。然而,纤维蛋白(原)和控制其沉积和清除的蛋白酶,包括(促)凝血酶和纤溶酶(原),可强有力地驱动急性和修复性炎症通路,进而影响组织损伤、重塑和修复。事实上,纤维蛋白(原)沉积是组织损伤的一个普遍特征,无论刺激事件的性质如何,包括机械损伤、感染或免疫紊乱所导致的损伤。纤维蛋白可通过多种细胞受体和机

止血和纤溶系统的经典作用是维持血管的完整性。任一系统异常都可能导致出血或血栓形成伴血管闭塞的主要病理终点。然而,纤维蛋白(原)和控制其沉积和清除的蛋白酶,包括(促)凝血酶和纤溶酶(原),可强有力地驱动急性和修复性炎症通路,进而影响组织损伤、重塑和修复。

事实上,纤维蛋白(原)沉积是组织损伤的一个普遍特征,无论刺激事件的性质如何,包括机械损伤、感染免疫紊乱所导致的损伤。纤维蛋白可通过多种细胞受体和机制招募白细胞来修饰炎症细胞功能的多个方面。关于凝血系统激活和纤维蛋白(原)沉积在炎症和组织损伤模型中的作用的研究揭示了一些共性,以及凝血和纤维蛋白溶解因子的上下游依赖性作用。

但是,任迫切需要明确纤维蛋白原介导炎症事件的精确时间和空间机制,或可指示组织损伤的严重程度,并协调对恢复正常器官功能至关重要的结构重塑和修复事件。目前的研究趋势提示未来的研究将会转向探究可用于组织损伤和疾病的新的止血因子靶向疗法。


原始出处:

James P. Luyendyk, Jonathan G. Schoenecker, and Matthew J. Flick. The multifaceted role of fibrinogen in tissue injury and inflammation. Blood  2018  :blood-2018-07-818211;  doi: https://doi.org/10.1182/blood-2018-07-818211

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1997265, encodeId=6840199e265f0, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Sep 17 06:52:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688802, encodeId=906e16888027f, content=<a href='/topic/show?id=8667e769859' target=_blank style='color:#2F92EE;'>#组织损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77698, encryptionId=8667e769859, topicName=组织损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7fe28645771, createdName=小几洁, createdTime=Mon Oct 14 15:52:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362611, encodeId=6899136261160, content=<a href='/topic/show?id=9f6ce72774d' target=_blank style='color:#2F92EE;'>#纤维蛋白原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77277, encryptionId=9f6ce72774d, topicName=纤维蛋白原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Mon Dec 10 00:52:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397676, encodeId=15df139e676c2, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Mon Dec 10 00:52:00 CST 2018, time=2018-12-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1997265, encodeId=6840199e265f0, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Sep 17 06:52:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688802, encodeId=906e16888027f, content=<a href='/topic/show?id=8667e769859' target=_blank style='color:#2F92EE;'>#组织损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77698, encryptionId=8667e769859, topicName=组织损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7fe28645771, createdName=小几洁, createdTime=Mon Oct 14 15:52:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362611, encodeId=6899136261160, content=<a href='/topic/show?id=9f6ce72774d' target=_blank style='color:#2F92EE;'>#纤维蛋白原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77277, encryptionId=9f6ce72774d, topicName=纤维蛋白原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Mon Dec 10 00:52:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397676, encodeId=15df139e676c2, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Mon Dec 10 00:52:00 CST 2018, time=2018-12-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1997265, encodeId=6840199e265f0, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Sep 17 06:52:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688802, encodeId=906e16888027f, content=<a href='/topic/show?id=8667e769859' target=_blank style='color:#2F92EE;'>#组织损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77698, encryptionId=8667e769859, topicName=组织损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7fe28645771, createdName=小几洁, createdTime=Mon Oct 14 15:52:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362611, encodeId=6899136261160, content=<a href='/topic/show?id=9f6ce72774d' target=_blank style='color:#2F92EE;'>#纤维蛋白原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77277, encryptionId=9f6ce72774d, topicName=纤维蛋白原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Mon Dec 10 00:52:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397676, encodeId=15df139e676c2, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Mon Dec 10 00:52:00 CST 2018, time=2018-12-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1997265, encodeId=6840199e265f0, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Sep 17 06:52:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688802, encodeId=906e16888027f, content=<a href='/topic/show?id=8667e769859' target=_blank style='color:#2F92EE;'>#组织损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77698, encryptionId=8667e769859, topicName=组织损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7fe28645771, createdName=小几洁, createdTime=Mon Oct 14 15:52:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362611, encodeId=6899136261160, content=<a href='/topic/show?id=9f6ce72774d' target=_blank style='color:#2F92EE;'>#纤维蛋白原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77277, encryptionId=9f6ce72774d, topicName=纤维蛋白原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Mon Dec 10 00:52:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397676, encodeId=15df139e676c2, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Mon Dec 10 00:52:00 CST 2018, time=2018-12-10, status=1, ipAttribution=)]

相关资讯

JAHA:基线血清纤维蛋白原升高对PCI后2年心血管严重不良事件的影响

基线纤维蛋白原水平升高与经皮冠脉介入治疗后的2年MACE相关。

Crit Care:早期纤维蛋白原浓缩物,治疗外伤性大出血的理想选择?

2018年6月,发表在《Crit Care》的一项由英国学者进行的多中心、随机、双盲、安慰剂对照试验,考察了早期纤维蛋白原浓缩物治疗外伤性大出血(E-FIT 1)的有效性。

CCLM:纤维蛋白原测定:国际和商业标准和质控样本的可交换性评估

许多临床实验室根据Clauss使用凝血率测定法测定抗凝血中的纤维蛋白原。本研究的目的是评估目前的国际纤维蛋白原标准(编号为09/264),三种商业化纤维蛋白原标准品和10种来自各种来源的冷冻干燥血浆质量控制样品的可交换性。

Blood:TLT-1是ALI/ARDS的独立的预后标志物,可减轻急性肺损伤

每年超过20万人罹患急性肺损伤(ALI)和急性呼吸窘迫综合征(ARDS),死亡率高达40%。虽然血小板也参与ALI/ARDS进展,但其确切作用尚不明确。研究人员在血小板上发现了在髓细胞中表达的触发受体(TREM)样转录本(TLT)-1,可结合纤维蛋白原,介导血块形成。因而研究人员推测血小板通过TLT-1主导ALI/ARDS的进展。为证明上述推测,研究人员回顾性检测ARDSNET临床试验样本的血浆s

ASO:纤维蛋白原可作为结肠癌患者的预后指征

在2013年4月25日在线出版的《外科肿瘤学年鉴》(Annals of Surgical Oncology)杂志上,韩国国立癌症中心的Ji Won Park博士等人发文指出,一种感染指标-纤维蛋白原可作为结肠癌预后指征。包括全身性感染在内的宿主性因素可对结直肠癌结局产生影响。这项研究目的为,评价可作为感染缓解率指标的纤维蛋白原及感染相关评分对结肠癌的预后意义。 研究人员对非转移性结肠癌患者病历进